KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Leases (2020 - 2025)

Aquestive Therapeutics has reported Current Leases over the past 6 years, most recently at $631000.0 for Q4 2025.

  • Quarterly results put Current Leases at $631000.0 for Q4 2025, up 23.73% from a year ago — trailing twelve months through Dec 2025 was $631000.0 (up 23.73% YoY), and the annual figure for FY2025 was $631000.0, up 23.73%.
  • Current Leases for Q4 2025 was $631000.0 at Aquestive Therapeutics, up from $601000.0 in the prior quarter.
  • Over the last five years, Current Leases for AQST hit a ceiling of $926000.0 in Q1 2022 and a floor of $255000.0 in Q4 2022.
  • Median Current Leases over the past 5 years was $555000.0 (2025), compared with a mean of $597200.0.
  • Biggest five-year swings in Current Leases: tumbled 71.64% in 2022 and later skyrocketed 52.94% in 2023.
  • Aquestive Therapeutics' Current Leases stood at $899000.0 in 2021, then tumbled by 71.64% to $255000.0 in 2022, then surged by 52.94% to $390000.0 in 2023, then surged by 30.77% to $510000.0 in 2024, then rose by 23.73% to $631000.0 in 2025.
  • The last three reported values for Current Leases were $631000.0 (Q4 2025), $601000.0 (Q3 2025), and $570000.0 (Q2 2025) per Business Quant data.